Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation

Zhou, Daiying; Ding, Ning; Du, Zhiyun; Cui, Xiaojie; Wang, Hong; Wei, Xingchuan; Conney, Allan H.; Zhang, Kun; Zheng, Xi

doi:10.3892/mmr.2014.2380

Cited by 42 publications

(36 citation statements)

References 33 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, a herbal formulation from Ecuador, BIRM effectively suppressed AR signaling in AR + (LAPC‐4 and LNCaP) cell lines and orthotopic models of CaP . Studies suggested that curcumin analogs suppress DHT‐induced AR activation in AR + CaP cells …”

Section: Discussionmentioning

confidence: 99%

A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer

Dahiya

Chandrasekaran

Kolluru

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

Androgen ablation therapy is the primary therapeutic option for locally advanced and metastatic castration-resistant prostate cancer (CRPC). We investigated therapeutic effect of a dietary metabolite Urolithin A (UroA) and dissected the molecular mechanism in CRPC cells. Treatment with UroA inhibited cell proliferation in both androgen receptor-positive (AR ) (C4-2B) and androgen receptor-negative (AR ) (PC-3) cells however, AR CaP cells were more sensitive to UroA treatment as compared with AR CaP cells. Inhibition of the AR signaling was responsible for the UroA effect on AR CaP cells. Ectopic expression of AR in PC-3 cells sensitized them to UroA treatment as compared to the vector-expresseing PC-3 cells, which suggests that AR could be a target of UroA. Similarly, in enzalutamide-resistant C4-2B cells, a downregulation of AR expression also suppressed cell proliferation which was observed with the UroA treatment. Oral administration of UroA significantly suppressed the growth of C4-2B xenografts (P = 0.05) compared with PC-3 xenografts (P = 0.069) without causing toxicity to animals. Immunohistochemistry analysis confirmed in vitro findings such as downregulation of AR/pAKT signaling in UroA-treated C4-2B tumors, which suggests that UroA may be a potent chemo-preventive and therapeutic agent for CRPC.

show abstract

Section: Discussionmentioning

confidence: 99%

A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer

Dahiya

Chandrasekaran

Kolluru

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…A recent clinical trial also demonstrated that a curcumin dose of 8 g per day when taken with Gemcitabine is safe and well tolerated as a supplement 7 . Other studies have demonstrated similar effects of curcumin and Docetaxel for ovarian cancer, 33 as well as curcumin and oxaliplatin for colon cancer 33, 37. Studies investigating the use of Docetaxel and curcumin as potential treatments for breast cancer have also shown that curcumin can be well tolerated in addition to the chemotherapy 36 …”

Section: Curcumin and Cancer Treatmentmentioning

confidence: 99%

Curcumin: An age-old anti-inflammatory and anti-neoplastic agent

Fadus

Lau

Bikhchandani

et al. 2017

Journal of Traditional and Complementary Medicine

264

140

View full text Add to dashboard Cite

Curcumin is a natural anti-inflammatory agent that has been used for treating medical conditions for many years. Several experimental and pharmacologic trials have demonstrated its efficacy in the role as an anti-inflammatory agent. Curcumin has been shown to be effective in treating chronic conditions like rheumatoid arthritis, inflammatory bowel disease, Alzheimer's and common malignancies like colon, stomach, lung, breast, and skin cancers. As treatments in medicine become more and more complex, the answer may be something simpler. This is a review article written with the objective to systematically analyze the wealth of information regarding the medical use of curcumin, the “curry spice”, and to understand the existent gaps which have prevented its widespread application in the medical community.

show abstract

“…The bioactive compound curcumin, derived from turmeric ( Curcuma longa ) has received considerable attention due to its anti-carcinogenic activities as demonstrated in numerous studies in animal models [43–47]. Importantly, several curcumin analogs have been shown to function as AR antagonists in the presence of AR and the AR co-activator, ARA70 [48].…”

Section: Natural Products Against Pcamentioning

confidence: 99%

“…Unfortunately, the oral bioavailability of curcumin is low and making improvements to this is currently an active area of research [3]. Several investigators demonstrated that curcumin analogs inhibit testosterone- or DHT-induced AR activity and inhibit growth of CWR-22Rv1 and LNCaP cells [43, 49]. …”

Section: Natural Products Against Pcamentioning

confidence: 99%

Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer

Kallifatidis

Hoy

Lokeshwar

2016

Seminars in Cancer Biology

View full text Add to dashboard Cite

Prostate cancer (PCa), a hormonally-driven cancer, ranks first in incidence and second in cancer related mortality in men in most Western industrialized countries. Androgen and androgen receptor (AR) are the dominant modulators of PCa growth. Over the last two decades multiple advancements in screening, treatment, surveillance and palliative care of PCa have significantly increased quality of life and survival following diagnosis. However, over 20% of patients initially diagnosed with PCa still develop an aggressive and treatment-refractory disease. Prevention or treatment for hormone-refractory PCa using bioactive compounds from marine sponges, mushrooms, and edible plants either as single agents or as adjuvants to existing therapy, has not been clinically successful. Major advancements have been made in the identification, testing and modification of the existing molecular structures of natural products. Additionally, conjugation of these compounds to novel matrices has enhanced their bio-availability; a big step towards bringing natural products to clinical trials. Natural products derived from edible plants (nutraceuticals), and common folk-medicines might offer advantages over synthetic compounds due to their broader range of targets, as compared to mostly single target synthetic anticancer compounds; e.g. kinase inhibitors. The use of synthetic inhibitors or antibodies that target a single aberrant molecule in cancer cells might be in part responsible for emergence of treatment refractory cancers. Nutraceuticals that target AR signaling (epigallocatechin gallate [EGCG], curcumin, and 5α-reductase inhibitors), AR synthesis (ericifolin, capsaicin and others) or AR degradation (betulinic acid, di-indolyl diamine, sulphoraphane, silibinin and others) are prime candidates for use as adjuvant or mono-therapies. Nutraceuticals target multiple pathophysiological mechanisms involved during cancer development and progression and thus have potential to simultaneously inhibit both prostate cancer growth and metastatic progression (e.g., inhibition of angiogenesis, epithelial-mesenchymal transition (EMT) and proliferation). Given their multi-targeting properties along with relatively lower systemic toxicity, these compounds offer significant therapeutic advantages for prevention and treatment of PCa. This review emphasizes the potential application of some of the well-researched natural compounds that target AR for prevention and therapy of PCa.

show abstract

Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation

Cited by 42 publications

References 33 publications

A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer

A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer

Curcumin: An age-old anti-inflammatory and anti-neoplastic agent

Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer

Contact Info

Product

Resources

About